Author

J. J. Marugan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:non-human primate· 1

Frequent Co-Authors

M. J. Henderson· 3 shared A. Kapoor· 2 shared A. E. Dulcey· 1 shared A. E. Owens· 1 shared A. Gehrlein· 1 shared A. Glogowska· 1 shared A. N. Nilson· 1 shared A. Simeonov· 1 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

M. J. Henderson

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Development of quantitative high-throughput screening assays to identify, validate, and optimize small-molecule stabilizers of misfolded β-glucocerebrosidase with therapeutic potential for Gaucher disease and Parkinson's disease

D. Williams, L. M. Glasstetter, T. T. Jong, A. Kapoor, S. Zhu, Y. Zhu, A. Gehrlein, D. J. Vocadlo, R. Jagasia, J. J. Marugan, E. Sidransky, M. J. Henderson, Y. Chen

This paper develops high-throughput assays to identify and optimize small-molecule stabilizers of misfolded β-glucocerebrosidase, showing NCGC326 reverses pathological accumulation and synergizes with proteostasis regulators.

bioRxiv · Mar 22, 2024 · PreprintPharmacology & Toxicology

Overcoming brain-derived therapeutic resistance in HER2+ breast cancer brain metastasis

D. Ippolitov, Y.-H. Lin, J. Spence, A. Glogowska, T. Thanasupawat, J. Beiko, M. R. Del Bigio, X. Xu, A. Wang, R. Calvo, A. Kapoor, J. J. Marugan, M. J. Henderson, T. Klonisch, S. Hombach-Klonisch

This study establishes a patient-derived HER2+ brain metastasis model and identifies Poziotinib as an effective RTKi for treating HER2+ breast cancer brain metastasis in mice.

bioRxiv · Feb 19, 2024 · PreprintCancer Biology

Identification and Characterization of ML321: a Novel and Highly Selective D2 Dopamine Receptor Antagonist with Efficacy in Animal Models that Predict Atypical Antipsychotic Activity

R. B. Free, A. N. Nilson, N. M. Boldizsar, T. Doyle, R. M. Rodriguiz, V. M. Pogorelov, M. Machino, K. H. Lee, J. W. Bertz, J. Xu, H. D. Lim, A. E. Dulcey, R. H. Mach, J. H. Woods, J. R. Lane, , D. R. Sibley

This paper develops ML321, a highly selective D2 dopamine receptor antagonist, showing efficacy in animal models predictive of atypical antipsychotic activity with fewer side effects.

bioRxiv · Nov 14, 2022Pharmacology & Toxicology

A real-time cellular thermal shift assay (RT-CETSA) to monitor target engagement

T. W. Sanchez, M. H. Ronzetti, A. E. Owens, M. Antony, T. Voss, E. Wallgren, D. Talley, K. Balakrishnan, G. Rai, J. J. Marugan, S. Michael, B. Baljinnyam, N. Southall, A. Simeonov, M. J. Henderson

The paper introduces RT-CETSA, a real-time cellular thermal shift assay that improves throughput and sensitivity for monitoring ligand-target engagement in cells.

bioRxiv · Jan 24, 2022 · PreprintPharmacology & Toxicology